What is Caplyta (lumateperone) used for, and what are its dosing recommendations, contraindications, precautions, and common adverse effects?

Caplyta (Lumateperone): Clinical Overview

Caplyta (lumateperone) is FDA-approved for treating schizophrenia and bipolar depression (bipolar I or II) in adults at a standard dose of 42 mg once daily, with dose adjustments required for hepatic impairment and CYP3A4 inhibitor use. 1

Approved Indications

• Schizophrenia in adults
• Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as:
  • Monotherapy
  • Adjunctive therapy with lithium or valproate 1

Notably, lumateperone is the only agent approved as adjunctive therapy for bipolar II depression 2.

Dosing Recommendations

Standard Dosing

• 42 mg once daily (with or without food)
• No titration required 1

Dose Adjustments

For CYP3A4 Inhibitors:

• Strong CYP3A4 inhibitors: Reduce to 10.5 mg once daily 1
• Moderate CYP3A4 inhibitors: Reduce to 21 mg once daily 1
• CYP3A4 inducers: Avoid concomitant use 1

For Hepatic Impairment:

• Moderate or severe hepatic impairment (Child-Pugh B or C): 21 mg once daily 1

Contraindications

Absolute contraindication:

• Known hypersensitivity to lumateperone or any component (reactions include pruritus, rash, allergic dermatitis, papular rash, generalized rash, and urticaria) 1

Boxed Warnings

Critical Safety Alerts

1. Increased mortality in elderly patients with dementia-related psychosis - Caplyta is NOT approved for this population 1

2. Suicidal thoughts and behaviors - Antidepressants increase risk in pediatric and young adult patients (age <25). Close monitoring required for clinical worsening and emergence of suicidal ideation. Caplyta is not approved for pediatric use 1

Warnings and Precautions

High-Risk Populations to Avoid

• Pregnant or breastfeeding women (may cause extrapyramidal and/or withdrawal symptoms in neonates with third-trimester exposure) 1, 3
• Children and adolescents 1, 3
• Elderly patients with dementia-related psychosis 1, 3
• Patients at risk for cerebrovascular disease (increased incidence of stroke and TIA) 1, 3
• Patients using CYP3A4 inducers or strong/moderate inhibitors (without dose adjustment) 1, 3
• Patients using alcohol or other sedating agents 3

Monitoring Requirements

Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring 1

Tardive Dyskinesia: Discontinue if clinically appropriate 1

Metabolic Changes: Monitor for:

• Hyperglycemia/diabetes mellitus
• Dyslipidemia
• Weight gain 1

Hematologic: Perform complete blood counts in patients with pre-existing low WBC or history of leukopenia/neutropenia. Consider discontinuation if clinically significant WBC decline occurs without other causative factors 1

Cardiovascular: Monitor heart rate and blood pressure, especially in patients with known cardiovascular/cerebrovascular disease and risk of dehydration or syncope (orthostatic hypotension and syncope risk) 1

Seizures: Use cautiously in patients with seizure history or conditions lowering seizure threshold 1

Cognitive/Motor Impairment: Caution when operating machinery 1

Common Adverse Effects

Schizophrenia (>5% and twice placebo):

• Somnolence/sedation
• Dry mouth 1

Bipolar Depression (>5% and twice placebo):

• Somnolence/sedation (12.5% vs 1.6% placebo)
• Dizziness (12.0% vs 2.1% placebo)
• Nausea (9.9% vs 1.6% placebo)
• Dry mouth 1, 4

Favorable Safety Profile

Notably minimal or absent:

• Extrapyramidal symptoms (EPS-related TEAEs only 1.0%) 5, 6, 7
• Metabolic dysfunction (significant decreases in total cholesterol, LDL, body weight, and prolactin when switching from other antipsychotics) 6
• Mania/hypomania treatment-emergent adverse events 4
• Movement disorders 7

The 42 mg dose demonstrated efficacy in schizophrenia (PANSS total score LSMD -4.2, effect size -0.3, p=0.02) 7 and bipolar depression (MADRS improvement, effect size -0.64 to -0.67) 4, 8, though discontinuation due to adverse events increased at this dose (RR=3.12) compared to lower doses 8.

Lumateperone's unique pharmacodynamic profile—full antagonist at postsynaptic D2 receptors with partial agonist effects at presynaptic D2 receptors, plus serotonin reuptake inhibition and glutamatergic modulation—achieves therapeutic effects with less than 50% D2 receptor occupancy, explaining its exceptionally favorable tolerability compared to other antipsychotics 2, 5.